COSCIENS Biopharma CSCIF Estimates

OTC CSCIF
$6.44 +0.02 (+0.31%)
At close: Oct 2, 2026 · 4:00 PM EDT
Analyst Estimates

COSCIENS Biopharma Inc. Revenue Estimates

Periods 12
Next Period Q4 24
Consensus 1.16 M

Analysts expect COSCIENS Biopharma Inc. to report revenue of 1.16 M for Q4 24, against a range of 1.10 M to 1.21 M. The most recent reported quarter, Q3 24, came in at 1.90 M, a 80.4% beat against the 1.05 M consensus.

Metric Q1 23Q2 23Q3 23Q4 23Q1 24Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25
Reported (Actual) 2.10 M2.20 M0.00100,000.004,000.002.30 M1.90 M-----
High Estimate 986,988.101.12 M2.28 M0.001.17 M1.22 M1.15 M1.21 M-846,292.851.82 M2.52 M2.09 M
Low Estimate 912,965.901.03 M2.14 M0.00976,988.381.12 M959,823.741.10 M-943,723.431.52 M2.14 M1.88 M
Consensus Estimate 949,977.001.08 M2.21 M0.001.07 M1.17 M1.05 M1.16 M-895,008.141.67 M2.33 M1.99 M
Analyst Estimates

COSCIENS Biopharma Inc. Earnings Per Share (EPS) Estimates

Periods 12
Next Period Q4 24
Consensus -10.75

Analysts expect COSCIENS Biopharma Inc. to report earnings per share of -10.75 for Q4 24, against a range of -11.34 to -10.16. The most recent reported quarter, Q3 24, came in at -5.55, a 44.8% beat against the -10.06 consensus.

Metric Q1 23Q2 23Q3 23Q4 23Q1 24Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25
Reported (Actual) -10.56-6.24-10.20-13.92-14.22-1.92-5.55-----
High Estimate -12.59-9.32-7.24-10.79-9.44-8.71-9.75-10.16-13.36-1.12-2.21-6.69
Low Estimate -14.01-10.48-7.76-11.75-10.52-10.17-10.37-11.34-15.08-1.24-2.65-8.05
Consensus Estimate -13.30-9.90-7.50-11.27-9.98-9.44-10.06-10.75-14.22-1.18-2.43-7.37

COSCIENS Biopharma Inc. Estimates API

Pull Wall Street consensus for COSCIENS Biopharma Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/estimates?ticker=CSCIF&mode=revenue&api_key=YOUR_API_KEY